Coyne Terrance P. sold 64,399 shares of Royalty Pharma plc at $53.98 for −$3.48M on May 26, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
EVP & CFO
EVP & CFO
Filed May 28, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$3,476,116.34Shares × reported price
Shares traded
64,399Class A Ordinary Shares
Price per share
$53.98Reported price. Read footnotes for ranges.
% of reported position traded
100%This security and ownership context
Holdings after
0Indirect · TPC RP EPA1 LLC
Trade date
May 26, 2026Sell
Filed
May 28, 2026, 4:48 PM ET2-day reporting delay
Accession
0001814876-26-000022Code S · Transaction 387404
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 64,399 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

RPRX price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
RPRX · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −9.4%1w ago −3.8%1d ago 0%
Returns since7d +1%30d +3.2%90d +13%180d1y

Footnotes in full

F1: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on February 24, 2026. F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.64 to $54.63 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.